Background: The diagnosis of Acute Myeloid Leukemia (AML) involves a comprehensive evaluation, including the morphology of myeloid cells, immunophenotypic characteristics, conventional cytogenetics, and genetic abnormalities in bone marrow and peripheral blood. Recent advances in genomics and other technologies have greatly enhanced our understanding of AML, revealing specific mutations, gene expression patterns, and epigenetic modifications that emphasize the disease’s heterogeneity. As a result, several biomarkers are becoming increasingly important for prognosis and treatment decisions. Integrating these biomarkers into diagnostic panels is essential for improving clinical outcomes, facilitating precise risk stratification, and supporting individualized treatment approaches.Aim of the Study: This study aims to evaluate the relationship between certain biomarkers in AML patients and controls using the ELISA technique.Methods: The study included 60 de novo AML patients from Alexandria University Hospitals and 60 matched controls based on age and sex.Results: To improve treatment responses and address resistance in AML, we assessed several emerging biomarkers with diagnostic and therapeutic potential. The study showed a significant relationship between these biomarkers in AML patients and controls, using the ELISA technique. This simple, reliable method could be implemented in diagnostic panels for newly diagnosed AML patients to guide treatment decisions.Conclusions: Our study demonstrates the significance of various biomarkers in AML patient assessment. These biomarkers hold considerable promise for improving diagnostic accuracy and therapeutic strategies, highlighting their potential role in optimizing AML management and enhancing patient outcomes.
Roushdy et al. (Sat,) studied this question.